|Publication number||US4137300 A|
|Application number||US 05/806,424|
|Publication date||Jan 30, 1979|
|Filing date||Jun 14, 1977|
|Priority date||Aug 20, 1976|
|Also published as||DE2736794A1|
|Publication number||05806424, 806424, US 4137300 A, US 4137300A, US-A-4137300, US4137300 A, US4137300A|
|Inventors||Pravin Sheth, Lewis J. Leeson|
|Original Assignee||Ciba-Geigy Corporation|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (7), Referenced by (55), Classifications (19)|
|External Links: USPTO, USPTO Assignment, Espacenet|
CROSS-REFERENCE TO RELATED APPLICATION
This is a continuation-in-part of application Ser. No. 716,314, filed Aug. 20, 1976 (now abandoned).
It is known that higher alkanols and/or alkanoic acids are useful ingredients of pharmaceutical dosage forms, either in regular tablets or in the core material of sustained release coated products. Prolamines are also known as edible coatings of food stuffs and pharmaceutical preparations, either in tablets, or smaller particles. Said materials are often utilized with other ingredients to make up highly complex mixtures, but have never been reported in the combination described below. Surprisingly it was found that the combination of said 3 or 4 basic ingredients alone results in well reproducible, sustained action dosage forms, the drug-release of which can be easily controlled by varying the relative proportions of said constituents, so that release times from about 8 to 24 hours can be achieved.
The present invention concerns and has for its object the provision of (1) a new sustained action dosage form comprising: (a) a core-mixture of a pharmacologically effective substance and at least two members selected from a higher alkanol and alkanoic acid melting above 25° C. and (b) an outer layer of a prolamine, as well as (2) a new process for the preparation of sustained release dosage forms, which consists in (c) mixing a pharmacologically effective substance with at least two members selected from a higher alkanol and alkanoic acid melting above 25° C.; if desired, heating the mixture to about 55-65° C., (d) granulating the resulting solid mixture with a solution of a prolamine, (e) evaporating the solvent of said solution and, (f) filling the resulting granules into capsules, or compressing them into tablets, if desired, with the use of other components, such as diluents, lubricants and/or disintegrating agents.
The pharmacologically effective substance is preferably a solid, also melting above 25° C., and may be either an acid or a base, but preferably a neutral substance, such as a salt.
A higher alkanol is preferably a straight chain primary alkanol with 14 to 24 carbon atoms, advantageously cetyl and stearyl alcohol, or various mixtures thereof, especially cetostearyl alcohol, which is an intimate mixture of at least 24% of cetyl alcohol and at most 76% of stearyl alcohol, but also such up to about 50% of cetyl and stearyl alcohol each. A higher alkanoic acid is also preferably a straight chain fatty acid with 14 to 24 carbon atoms, such as myristic, palmitic and/or stearic acid. A mixtures of said alcohols and acids may be used, or natural mixtures obtained from corresponding fats or waxes.
The prolamines are simple, globular proteins, preferably those obtained from grains, advantageously zein, but also gliadin and/or hordenin.
The proportions of drug substance:alcohol/acid:prolamine may vary from about 100:5:3 to about 100:200:80, for tablets preferable from about 100:17:4 to about 100:26:8, especially 100:22:6, and for capsules preferably from about 100:25:5 to about 100:35:7, especially 100:30:6. This mixture may contain additional components in order to become manageable for tabletting or capsule-filling. Said compounds are, for example diluents, such as sugars, e.g. lactose or sucrose; mannitol, cellulose, starches or calcium phosphates; or lubricants, such as alkaline earth metal salts of higher fatty acids, advantageously magnesium stearate, silica, talcum, polyethyleneglycol, teflon or vegetable fats; or disintegrating agents, such as sodium carboxymethyl-starch, other starches, alginic acid, its alkali metal salts or surface active agents, e.g. sodium lauryl sulfate. The amount of said additional components ranges from about 0.5 to 100%, preferably about 2 to 50% of the drug substance.
All the above-mentioned substances are utilized in the form of fine powders, passing sieves with openings of about 0.5 to 1.5 mm. The mixture according to (1a) is ground again and should pass through sieves with openings of about 1 to 2 mm.
In the process liquid under item (2) said drug substance and the higher alkanol or alkanoic acid can either be mixed in the form of said fine solid powder, or they are fused together, or one component is dissolved in the lower melting other component, e.g. at about 60° C. The resulting mixture is cooled and ground, if necessary, in order to obtain particles in the range between about 0.5 and about 3 mm each. They are granulated with said prolamine solution, the solvent of which is preferable a mixture of an aqueous lower alkanol and/or alkanone, advantageously ethanol or acetone, and a halogenated lower alkane, e.g. a lower alkylene chloride, advantageously methylene chloride, for example, in the proportions water:alkanol:alkylene chloride between about 1:9:10 to about 1:10:15. Said solution is gradually poured onto the former mixture so that its particles receive an outer layer of the dissolved prolamine.
The resulting wet granulate is dried in a suitable dryer, preferably between about 25 and 30° C., the dried granules blended with said lubricant and milled through a comminuting machine, if necessary.
The resulting granulate according to the invention can either be compressed into tablets, if necessary with an additional amount of lubricant, e.g. magnesium stearate, or the tablets are broken down by a comminuting machine or any suitable grinding equipment, fitted with a screen with openings preferably between 0.5 and 2 mm, and filled into hard gelatin capsules, or said granulate is filled into capsules, preferably hard gelatin capsules, as such, or in admixture with more lubricants and/or fillers, for example, silica, talcum, starches, sugars, cellulose or sodium carboxy-methyl-starch.
The resulting tablets may be conventionally film or sugar coated, either for stability or aesthetic purposes. The following examples illustrate the invention and are not to be construed as being limitations thereof. Temperatures are given in degrees Centigrade and all parts, wherever given, are parts by weight.
Preparation of 2,000,000 tablets each containing 100 mg of drug substance:
______________________________________Formula:Tripelennamine hydrochloride 200.00 kgCetostearyl alcohol 44.00 kgZein 12.00 kgMagnesium stearate 6.00 kgAnhydrous ethanol 22.22 kgMethylene chloride 22.22 kgPurified water 2.77 kg______________________________________
The drug substance is passed through a screen with openings of about 0.5-1.5 mm to break up any lumps. It is then mixed with cetostearyl alcohol and heated until the powders fuse and form granules at about 55°-65°. The granules are cooled and passed through a comminuting machine and screened through openings of about 1-2 mm. The zein is suspended in the aqueous ethanol and the methylene chloride is added while mixing. The resulting solution is poured onto said granules, using suitable granulating equipment. The wet granulate is dried overnight at about 30°, blended with about half the magnesium stearate, the whole milled through a comminuting machine and passed through a screen with about 0.5-2 mm openings. The granulate is mixed with the balance of the magnesium stearate and compressed into 131 mg tablets using 7.1 mm tooling.
Preparation of 100,000 capsules each containing 100 mg of drug substance:
______________________________________Formula:Hydrochlorothiazide 10.00 kgCetostearyl alcohol 3.00 kgZein 0.60 kgMagnesium stearate 0.25 kgAnhydrous ethanol 1.62 kgMethylene chloride 1.80 kgPurified water 0.18 kgSodium carboxymethyl-starch 1.00 kgSilica 0.05 kg______________________________________
The drug substance, cetostearyl alcohol and part of the magnesium stearate are mixed for 3 minutes and heated to 55°-65° to form granules. They are cooled to 25°-30° and granulated with the zein solution in the aqueous ethanolmethylene chloride. The granulate is dried overnight at 30°, comminuted and passed through a screen with 2-3 mm openings. The resulting powder is mixed with 0.1 kg of magnesium stearate for 5 minutes and compressed into 2.65 g slugs of 7.2 mm thickness. They are broken in a comminuting machine, passed through a screen with 1 mm openings and the powder blended with the remaining magnesium stearate, sodium carboxymethyl-starch and silica for 10 minutes. 149 mg of the resulting mixture is filled in hard gelatin capsules, using a capsule filling machine.
Preparation of 2,500,000 tablets each containing 50 mg of drug substance:
______________________________________Formula:Tripelennamine hydrochloride 125.00 kgLactose anhydrous 67.50 kgCetostearyl alcohol 50.00 kgZein 12.50 kgMagnesium stearate 7.50 kgAnhydrous ethanol 27.00 kgMethylene chloride 25.00 kgPurified water 3.00 kg______________________________________
According to Example 1, except that 105 mg tablets are compressed, using 6.3 mm tooling.
Preparation of 2,500,000 tablets each containing 10 mg of drug substance:
______________________________________Formula:Methylphenidate hydrochloride 25.00 kgLactose 205.00 kgCetostearyl alcohol 40.00 kgZein 12.50 kgMagnesium stearate 5.00 kgAnhydrous ethanol 33.75 kgMethylene chloride 18.75 kgPurified water 3.75 kg______________________________________
According to Example 1, except that 115 mg tablets are compressed, using 6.3 mm tooling.
Preparation of 2,000,000 tablets each containing 20 mg of drug substance:
______________________________________Formula:Methylphenidate hydrochloride 40.00 kgCetostearyl alcohol 40.00 kgLactose 184.00 kgZein 12.00 kgMagnesium stearate 4.00 kgAnhydrous ethanol 32.40 kgMethylene chloride 18.00 kgPurified water 3.60 kg______________________________________
According to Example 1, except that 140 mg tablets are compressed, using 7.1 mm tooling.
Preparation of 1,000,000 tablets each containing 160 mg of drug substance:
______________________________________Formula:Oxprenolol hydrochloride 160.00 kgLactose anhydrous 30.00 kgCetostearyl alcohol 10.00 kgZein 6.00 kgMagnesium stearate 4.00 kgAnhydrous ethanol 16.20 kgMethylene chloride 9.00 kgPurified water 1.80 kg______________________________________
According to Example 1, except that 237 mg tablets are compressed, using 8.7 mm tooling.
In said Examples 3 to 6, the drug substance is mixed first with the lactose and the resultant mixture is processed as the tripelennamine hydrochloride, shown in Example 1 herein.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US874310 *||Jan 16, 1906||Dec 17, 1907||Eugene Donard||Pharmaceutical coating.|
|US2895880 *||May 13, 1955||Jul 21, 1959||Smith Kline French Lab||Sustained release pharmaceutical product|
|US3062720 *||May 20, 1959||Nov 6, 1962||Philips Roxane||Sustained release pharmaceutical tablet|
|US3079303 *||Dec 11, 1958||Feb 26, 1963||Smith Kline French Lab||Basic tablet granulation and process of using same|
|US3108046 *||Oct 17, 1962||Oct 22, 1963||Smith Kline French Lab||Method of preparing high dosage sustained release tablet and product of this method|
|US3147187 *||Sep 10, 1962||Sep 1, 1964||Don Hall Lab||Sustained release pharmaceutical|
|US3184386 *||Aug 29, 1962||May 18, 1965||Burroughs Wellcome Co||Prolonged action medicinal tablets|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US4609542 *||Jul 1, 1985||Sep 2, 1986||Elan Corporation, P.L.C.||New pharmaceutical forms for administration of medicaments by oral route, with programmed release|
|US4680172 *||Mar 5, 1985||Jul 14, 1987||Ciba-Geigy Corporation||Devices and methods for treating memory impairment|
|US4690822 *||Mar 12, 1986||Sep 1, 1987||Fujisawa Pharmaceutical Co., Ltd.||Novel drug carrier and pharmaceutical preparation comprising the same|
|US4726951 *||Jul 1, 1985||Feb 23, 1988||Elan Corporation P.L.C.||New pharmaceutical forms for administration of medicaments by oral route, with programmed release|
|US4765985 *||May 20, 1987||Aug 23, 1988||Ciba-Geigy Corporation||Devices and methods for treating memory impairment|
|US5021248 *||Sep 1, 1989||Jun 4, 1991||Enzytech, Inc.||Hydrophobic protein microparticles and preparation thereof|
|US5112625 *||Aug 9, 1990||May 12, 1992||Wm. Wrigley Jr. Company||Aqueous zein coated sweeteners and other ingredients for chewing gum|
|US5160742 *||Dec 31, 1991||Nov 3, 1992||Abbott Laboratories||System for delivering an active substance for sustained release|
|US5192563 *||Dec 17, 1991||Mar 9, 1993||Wm. Wrigley, Jr. Company||Strongly mint-flavored chewing gums with reduced bitterness and harshness|
|US5599556 *||May 19, 1994||Feb 4, 1997||Abbott Laboratories||Prolamine coatings for taste masking|
|US5609909 *||Apr 13, 1995||Mar 11, 1997||Abbott Laboratories||Prolamine coatings for taste masking|
|US5643905 *||Jan 10, 1994||Jul 1, 1997||Therapie-System Gmbh & Co., Kg||Pharmaceutical formulation for the treatment of nicotine dependence|
|US5869086 *||Apr 25, 1994||Feb 9, 1999||Lts Lohmann Therapie-Systeme Gmbh||Systems for the controlled release of pilocarpine|
|US6114347 *||Dec 6, 1994||Sep 5, 2000||Lts Lohmann Therapie-Systeme Gmbh||Pharmaceutical formulation for the prophylaxis and pretreatment of a poisoning caused by organophosphorus cholinesterase inhibitors|
|US6335388||Oct 2, 1998||Jan 1, 2002||Lavipharm Laboratories Inc.||Prolamine-plant polar lipid composition, its method of preparation and applications thereof|
|US6361827||Dec 25, 1998||Mar 26, 2002||Showa Sangyo Co., Ltd.||Method of imparting water resistance to molded polysaccharide|
|US6548510||Feb 8, 2000||Apr 15, 2003||Lts Lohmann Therapie Systeme Ag||Pharmaceutical composition containing deoxypeganine for the treatment of nicotine dependence|
|US6613353||Nov 22, 2000||Sep 2, 2003||Pii Drug Delivery, Llc||Pharmaceutical formulations|
|US6627631 *||Feb 8, 2000||Sep 30, 2003||Lts Lohmann Therapie-Systeme Ag||Pharmaceutical composition containing desoxypeganine for the treatment of alcoholism|
|US6635284||Mar 11, 1998||Oct 21, 2003||Celegene Corporation||Delivery of multiple doses of medications|
|US6919373||Feb 19, 1999||Jul 19, 2005||Alza Corporation||Methods and devices for providing prolonged drug therapy|
|US6930129||Mar 8, 2001||Aug 16, 2005||Alza Corporation||Methods and devices for providing prolonged drug therapy|
|US7115631||Jul 16, 2002||Oct 3, 2006||Celgene Corporation||Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate|
|US7431944||Jun 10, 2003||Oct 7, 2008||Celgene Corporation||Delivery of multiple doses of medications|
|US7459560||Feb 23, 2006||Dec 2, 2008||Celgene Corporation||Processes and intermediates for resolving piperidyl acetamide stereoisomers|
|US8084059||Sep 15, 2006||Dec 27, 2011||Alza Corporation||Antidepressant dosage form|
|US8163798||Aug 12, 2003||Apr 24, 2012||Alza Corporation||Methods and devices for providing prolonged drug therapy|
|US8629179||Oct 19, 2009||Jan 14, 2014||Alza Corporation||Methods and devices for providing prolonged drug therapy|
|US9000038||Mar 13, 2013||Apr 7, 2015||Alza Corporation||Methods and devices for providing prolonged drug therapy|
|US9029416||Aug 12, 2003||May 12, 2015||Alza Corporation||Methods and devices for providing prolonged drug therapy|
|US9144549||Mar 13, 2013||Sep 29, 2015||Alza Corporation||Methods and devices for providing prolonged drug therapy|
|US9393192||Apr 22, 2009||Jul 19, 2016||Alza Corporation||Methods and dosage forms for controlled delivery of paliperidone and risperidone|
|US20020198234 *||Jul 16, 2002||Dec 26, 2002||Woodcock Washburn Llp||Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate|
|US20040091532 *||Jun 10, 2003||May 13, 2004||Mehta Atul M.||Delivery of multiple doses of medications|
|US20040204456 *||Apr 8, 2004||Oct 14, 2004||Celgene Corporation||Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate|
|US20050025831 *||Aug 12, 2003||Feb 3, 2005||Alza Corporation||Methods and devices for providing prolonged drug therapy|
|US20050025832 *||Aug 12, 2003||Feb 3, 2005||Alza Corporation||Methods and devices for providing prolonged drug therapy|
|US20050208132 *||Feb 4, 2005||Sep 22, 2005||Gayatri Sathyan||Methods and dosage forms for reducing side effects of benzisozazole derivatives|
|US20050232995 *||Feb 4, 2005||Oct 20, 2005||Yam Nyomi V||Methods and dosage forms for controlled delivery of paliperidone and risperidone|
|US20050238709 *||Aug 12, 2003||Oct 27, 2005||Alza Corporation||Methods and devices for providing prolonged drug therapy|
|US20050239830 *||Apr 26, 2004||Oct 27, 2005||Vikram Khetani||Methods of diminishing co-abuse potential|
|US20060030587 *||Oct 6, 2005||Feb 9, 2006||Celgene Corporation||Method of treating attention deficit disorders with d-threo methylphenidate|
|US20060127421 *||Dec 8, 2005||Jun 15, 2006||Celgene Corporation||Treatment using D-threo methylphenidate|
|US20060142583 *||Feb 23, 2006||Jun 29, 2006||Vikram Khetani||Processes and intermediates for resolving piperidyl acetamide stereoisomers|
|US20060183774 *||Apr 11, 2006||Aug 17, 2006||Celgene Corporation||Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate|
|US20070009600 *||Sep 15, 2006||Jan 11, 2007||Edgren David E||Antidepressant dosage form|
|US20090062336 *||Nov 12, 2008||Mar 5, 2009||Celgene Corporation||Methods of Diminishing Co-Abuse Potential|
|US20090088455 *||Dec 9, 2008||Apr 2, 2009||Celgene Corporation||Chronic, Bolus Adminstration Of D-Threo Methylphenidate|
|US20090202631 *||Apr 22, 2009||Aug 13, 2009||Yam Nyomi V||Methods and dosage forms for controlled delivery of paliperidone and risperidone|
|US20100093796 *||Oct 19, 2009||Apr 15, 2010||Gupta Suneel K||Methods and devices for providing prolonged drug therapy|
|US20110118310 *||May 19, 2011||Celgene Corporation||Treatment Using D-Threo Methylphenidate|
|US20110201645 *||Aug 18, 2011||Zeitlin Andrew L||Method Of Treating Attention Deficit Disorders With D-Threo Methylphenidate|
|EP1541147A1 *||Jun 9, 1998||Jun 15, 2005||Maghsoud M. Dariani||Improved delivery of multiple doses of a methylphenidate drug|
|WO1998026766A1 *||Dec 17, 1997||Jun 25, 1998||Fractales Biotech||Biodegradable capsule with a prolamin base|
|WO1999003471A1 *||Jun 9, 1998||Jan 28, 1999||Mehta, Atul, M.||Improved delivery of multiple doses of medications|
|U.S. Classification||424/460, 424/468|
|International Classification||A61K9/16, A61K9/64, A61K9/20, A61K9/50, A61K47/42, A61K9/48, A61K9/00, A61K47/30|
|Cooperative Classification||A61K9/5052, A61K9/4866, A61K9/2013, A61K9/1617, A61K9/2063|
|European Classification||A61K9/20H4, A61K9/20H6H, A61K9/50H6H, A61K9/48H6|